MX2011009597A - Deteccion mejorada de la expresion del gen. - Google Patents

Deteccion mejorada de la expresion del gen.

Info

Publication number
MX2011009597A
MX2011009597A MX2011009597A MX2011009597A MX2011009597A MX 2011009597 A MX2011009597 A MX 2011009597A MX 2011009597 A MX2011009597 A MX 2011009597A MX 2011009597 A MX2011009597 A MX 2011009597A MX 2011009597 A MX2011009597 A MX 2011009597A
Authority
MX
Mexico
Prior art keywords
gene expression
improved detection
oligonucleotide
primer
detection
Prior art date
Application number
MX2011009597A
Other languages
English (en)
Spanish (es)
Inventor
Gaetan Otto
Catherine Bovie
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MX2011009597A publication Critical patent/MX2011009597A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2011009597A 2009-03-17 2010-03-17 Deteccion mejorada de la expresion del gen. MX2011009597A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16093509P 2009-03-17 2009-03-17
PCT/EP2010/001674 WO2010105815A2 (en) 2009-03-17 2010-03-17 Improved detection of gene expression

Publications (1)

Publication Number Publication Date
MX2011009597A true MX2011009597A (es) 2012-05-29

Family

ID=42224406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009597A MX2011009597A (es) 2009-03-17 2010-03-17 Deteccion mejorada de la expresion del gen.

Country Status (14)

Country Link
US (1) US20120039993A1 (enExample)
EP (1) EP2408933A2 (enExample)
JP (1) JP2012520663A (enExample)
KR (1) KR20120002534A (enExample)
CN (1) CN102575284A (enExample)
AU (1) AU2010225125A1 (enExample)
BR (1) BRPI1009873A2 (enExample)
CA (1) CA2755734A1 (enExample)
EA (1) EA021100B1 (enExample)
IL (1) IL215182A0 (enExample)
MX (1) MX2011009597A (enExample)
SG (1) SG174877A1 (enExample)
WO (1) WO2010105815A2 (enExample)
ZA (1) ZA201107175B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481813A1 (en) * 2011-02-01 2012-08-01 Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano Markers of cutaneous melanoma and uses thereof
KR20130081515A (ko) 2012-01-09 2013-07-17 삼성전자주식회사 Led 패키지용 기판 및 led 패키지 제조방법
US9096905B2 (en) * 2012-02-23 2015-08-04 Medical Diagnostic Laboratories, Llc Detecting DNA methylation of BCL2, CDKN2A and NID2 genes to predict bladder cancer in humans
EP2971156B1 (en) 2013-03-15 2020-07-15 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
US20180187267A1 (en) * 2017-01-05 2018-07-05 Michael J. Powell Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence
WO2016003810A1 (en) 2014-07-02 2016-01-07 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
CN104611453B (zh) * 2015-02-28 2016-08-24 基因科技(上海)有限公司 诊断基因甲基化的探针组及其应用
WO2016208466A1 (ja) * 2015-06-22 2016-12-29 ウシオ電機株式会社 検出対象物質の検出方法
DE102016005947B3 (de) * 2016-05-16 2017-06-08 Dimo Dietrich Verfahren zur Abschätzung der Prognose und zur Prädiktion des Ansprechens auf eine Immuntherapie von Patienten mit malignen Erkrankungen
US11685955B2 (en) 2016-05-16 2023-06-27 Dimo Dietrich Method for predicting response of patients with malignant diseases to immunotherapy
CN109400697B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术(广东)有限公司 一种识别prame抗原短肽的tcr及其相关组合物
US11441182B2 (en) * 2018-08-08 2022-09-13 Virginia Commonwealth University Multiplexed and recyclable single-molecule sensors for quantitative analysis of nucleic-acid biomarkers
JP7216995B2 (ja) * 2018-12-05 2023-02-02 学校法人関西医科大学 胸腺癌バイオマーカー及び胸腺腫瘍の予後予測マーカー
CN110387421A (zh) * 2019-08-28 2019-10-29 深圳市新合生物医疗科技有限公司 用于肺癌检测的DNA甲基化qPCR试剂盒及使用方法
RU2760573C1 (ru) * 2021-01-20 2021-11-29 Общество с ограниченной ответственностью "Эс Джи" Набор олигонуклеотидных праймеров и флуоресцентно-меченых зондов для выявления эпигенетических маркеров рака шейки матки

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
CA1340843C (en) 1987-07-31 1999-12-07 J. Lawrence Burg Selective amplification of target polynucleotide sequences
US6417165B1 (en) 1988-03-27 2002-07-09 Ludwig Institute For Cancer Research NY-ESO-1-peptide derivatives, and uses thereof
US6252052B1 (en) 1996-10-03 2001-06-26 Cornell Research Foundation, Inc Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US6723832B1 (en) 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
KR0148265B1 (ko) 1988-12-16 1998-10-15 에프.지이.엠 헤르만스 자가-지속 서열 복제 시스템
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6251603B1 (en) 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
DE19752759A1 (de) 1997-11-28 1999-07-01 Basf Coatings Ag Triboelektrisch aufladbare Pulverlacke
DE69942214D1 (de) 1998-02-05 2010-05-12 Glaxosmithkline Biolog Sa Verfahren zur Reinigung oder Herstellung der MAGE Protein
US6140050A (en) 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
DK1104306T3 (da) 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
US6800730B1 (en) 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
US6605711B1 (en) 1999-11-15 2003-08-12 Ludwig Institute For Cancer Research NY-ESO-1 peptide derivatives, and uses thereof
US6689742B1 (en) 2000-02-25 2004-02-10 Chancellors, Masters And Scholars Of The University Of Oxford NY-ESO-1 peptide derivatives, and uses thereof
US6756044B1 (en) 2000-02-09 2004-06-29 Genvec, Inc. Antigenic complexes and methods
KR100987360B1 (ko) 2001-11-21 2010-10-12 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법
US20030134404A1 (en) 2001-11-26 2003-07-17 Lochrie Michael A. Methods for producing stocks of recombinant AAV virions
EP1482795B1 (en) 2002-02-04 2009-11-11 Corixa Corporation New immunoeffector compounds
WO2004067726A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Isothermal reactions for the amplification of oligonucleotides
US20050026183A1 (en) * 2003-05-15 2005-02-03 Jian-Bing Fan Methods and compositions for diagnosing conditions associated with specific DNA methylation patterns
DE10329240A1 (de) * 2003-06-24 2005-01-20 Epigenomics Ag Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
EP1904649A2 (en) * 2005-07-18 2008-04-02 Epigenomics AG Compositions and methods for cancer diagnostics comprising pan-cancer markers
AU2008207025B2 (en) 2007-01-15 2012-08-23 Glaxosmithkline Biologicals Sa Vaccine
PL2118128T3 (pl) * 2007-01-15 2013-03-29 Glaxosmithkline Biologicals Sa Białka fuzyjne zawierające antygeny odrzucenia nowotworu NY-ESO-1 i LAGE-1
US20120142546A1 (en) * 2007-12-10 2012-06-07 The Johns Hopkins University Hypomethylated genes in cancer
WO2009108917A2 (en) * 2008-02-29 2009-09-03 Oncomethylome Sciences, S.A. Markers for improved detection of breast cancer

Also Published As

Publication number Publication date
KR20120002534A (ko) 2012-01-05
WO2010105815A3 (en) 2010-11-25
AU2010225125A1 (en) 2011-10-20
JP2012520663A (ja) 2012-09-10
EA021100B1 (ru) 2015-04-30
IL215182A0 (en) 2011-12-29
SG174877A1 (en) 2011-11-28
ZA201107175B (en) 2012-06-27
EP2408933A2 (en) 2012-01-25
CA2755734A1 (en) 2010-09-23
CN102575284A (zh) 2012-07-11
WO2010105815A2 (en) 2010-09-23
EA201171131A1 (ru) 2012-03-30
US20120039993A1 (en) 2012-02-16
BRPI1009873A2 (pt) 2016-03-08

Similar Documents

Publication Publication Date Title
MX2011009597A (es) Deteccion mejorada de la expresion del gen.
MX2010002965A (es) Deteccion mejorada de la expresion de mage-a.
NZ591416A (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
NZ588658A (en) Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor
NZ595955A (en) Oligonucleotide comprising an inosine for treating dmd
WO2009108866A3 (en) Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof
NZ585327A (en) Lna antagonists targeting the androgen receptor
WO2008087040A3 (en) Methods and nucleic acids for analyses of cell proliferative disorders
NZ598724A (en) Soybean transgenic event mon 87708 and methods of use thereof
NZ599032A (en) Modulation of huntingtin expression
WO2011005860A3 (en) 5' phosphate mimics
IL202530A0 (en) Targeted nucleotide exchange with improved modified oligonucleotides
MX2009012482A (es) Oligonucleotidos de clase a con potencia inmunoestimuladora.
WO2011073629A3 (en) Cancer diagnosis and treatment
WO2011043809A9 (en) Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
MX2013008252A (es) Firma de pronostico para la recurrencia de cancer colorrectal.
IN2012DN01979A (enExample)
NZ706930A (en) Genetic markers for myb28
MY184632A (en) A method of identifying parentage in freshwater prawn macrobrachium rosenbergii
MX2013003698A (es) Agente preventivo o terapeutico contra la fibrosis.
WO2010007083A3 (en) Methods and nucleic acids for analyses of cell proliferative disorders
EP2107114A4 (en) PRIMER AND PROBE FOR DETECTING MYCOBACTERIUM AVIUM AND PROCESS FOR DETECTING MYCOBACTERIUM AVIUM USING THE PRIMER OR THE PROBE
WO2009065511A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders
MX2009004382A (es) Variaciones geneticas asociadas con tumores.
NZ602920A (en) Kras primers and probes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal